Persistent Cytopenias after Chimeric Antigen Receptor T-Cell Immunotherapy for CD19+ Aggressive Lymphoma: A Single Institution Experience

George Nahas; Krishna V. Komanduri; Denise Pereira; Cara L. Benjamin; Amer Beitinjaneh; Antonio M Jimenez; Mark Goodman; Trent P Wang; Claudette G Edwards; Lazaros J. Lekakis

doi:10.1016/J.BBMT.2018.12.324

Persistent Cytopenias after Chimeric Antigen Receptor T-Cell Immunotherapy for CD19+ Aggressive Lymphoma: A Single Institution Experience

George Nahas, Krishna V. Komanduri, Denise Pereira, Cara L. Benjamin, Amer Beitinjaneh, Antonio M Jimenez, Mark Goodman, Trent P Wang, Claudette G Edwards, Lazaros J. Lekakis

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Biology of Blood and Marrow Transplantation
Volume	25
DOIs	https://doi.org/10.1016/J.BBMT.2018.12.324
State	Published - Mar 1 2019

Disciplines

Gastroenterology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1016/J.BBMT.2018.12.324License: Unspecified

Cite this

Nahas, G., Komanduri, K. V., Pereira, D., Benjamin, C. L., Beitinjaneh, A., Jimenez, A. M., Goodman, M., Wang, T. P., Edwards, C. G., & Lekakis, L. J. (2019). Persistent Cytopenias after Chimeric Antigen Receptor T-Cell Immunotherapy for CD19+ Aggressive Lymphoma: A Single Institution Experience. Biology of Blood and Marrow Transplantation, 25. https://doi.org/10.1016/J.BBMT.2018.12.324

Nahas, G, Komanduri, KV, Pereira, D, Benjamin, CL, Beitinjaneh, A, Jimenez, AM, Goodman, M, Wang, TP, Edwards, CG & Lekakis, LJ 2019, 'Persistent Cytopenias after Chimeric Antigen Receptor T-Cell Immunotherapy for CD19+ Aggressive Lymphoma: A Single Institution Experience', Biology of Blood and Marrow Transplantation, vol. 25. https://doi.org/10.1016/J.BBMT.2018.12.324

@article{82f7863e06734ad0a4c80bac3958a37b,

title = "Persistent Cytopenias after Chimeric Antigen Receptor T-Cell Immunotherapy for CD19+ Aggressive Lymphoma: A Single Institution Experience",

author = "George Nahas and Komanduri, {Krishna V.} and Denise Pereira and Benjamin, {Cara L.} and Amer Beitinjaneh and Jimenez, {Antonio M} and Mark Goodman and Wang, {Trent P} and Edwards, {Claudette G} and Lekakis, {Lazaros J.}",

note = "Chimeric antigen receptor (CAR) T cell therapy is FDA-approved for the treatment of refractory or multiple-relapsed CD19+ B-NHL. Despite its ability to induce rapid and durable responses, it carries the risk of significant toxicities including cytokine release syndrome (CRS) and reversible encephalopathy.",

year = "2019",

month = mar,

day = "1",

doi = "10.1016/J.BBMT.2018.12.324",

language = "American English",

volume = "25",

journal = "Biology of Blood and Marrow Transplantation",

}

TY - JOUR

T1 - Persistent Cytopenias after Chimeric Antigen Receptor T-Cell Immunotherapy for CD19+ Aggressive Lymphoma: A Single Institution Experience

AU - Nahas, George

AU - Komanduri, Krishna V.

AU - Pereira, Denise

AU - Benjamin, Cara L.

AU - Beitinjaneh, Amer

AU - Jimenez, Antonio M

AU - Goodman, Mark

AU - Wang, Trent P

AU - Edwards, Claudette G

AU - Lekakis, Lazaros J.

N1 - Chimeric antigen receptor (CAR) T cell therapy is FDA-approved for the treatment of refractory or multiple-relapsed CD19+ B-NHL. Despite its ability to induce rapid and durable responses, it carries the risk of significant toxicities including cytokine release syndrome (CRS) and reversible encephalopathy.

PY - 2019/3/1

Y1 - 2019/3/1

UR - https://www.bbmt.org/article/S1083-8791(18)31146-7/fulltext

U2 - 10.1016/J.BBMT.2018.12.324

DO - 10.1016/J.BBMT.2018.12.324

M3 - Article

VL - 25

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

ER -

Persistent Cytopenias after Chimeric Antigen Receptor T-Cell Immunotherapy for CD19+ Aggressive Lymphoma: A Single Institution Experience

Disciplines

Access to Document

Other files and links

Cite this